Edwards Lifesciences — Feb 11, 2025 release

Highlights and Outlook • Q4 sales grew 9% to $1.39 billion 1 , better than expected, with strength across all product groups • Q4 TAVR sales grew 6%; constant currency 2 sales grew 5% • Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth • Q4 EPS of $0.58 1 ; adjusted 2 EPS of $0.59, driven by strong top-line performance • Presented results of two practice-changing FDA clinical trials, EARLY TAVR and TRISCEND II • Reiterating 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50 • Continuing to expect mid-year asymptomatic TAVR indication approval in the U.S. • Increasing contributions from an expanding set of structural heart therapies in 2026 and beyond “It was a year of meaningful progress for Edwards in 2024, as our 16,000 employees advanced life-saving structural heart innovations for patients around the world. We exited the year in a strong position with three important growth drivers: TAVR, Mitral and Tricuspid, and two emerging opportunities in Structural Heart Failure and Aortic Regurgitation,” said Bernard Zovighian, Edwards’ CEO. “In 2025, we expect to build on many catalysts across our businesses that will contribute to growth. Going forward, the investments and actions we’ve taken to advance our strategy will position us for continuing strong performance. I am optimistic about the tremendous opportunities in front of us to transform structural heart patient care.” Transcatheter Aortic Valve Replacement (TAVR) In the fourth quarter, the company reported TAVR sales of $1.04 billion, which grew 6% versus the prior year, or 5% on a constant currency basis. Full-year 2024 global sales of $4.1 billion increased 6% year-over-year. U.S. and OUS sales